The present disclosure relates to implantable devices and, more particularly, to prosthetic valves for implantation into body ducts, such as native-heart-valve annuluses.
The human heart can suffer from various valvular diseases, which can result in significant malfunctioning of the heart and ultimately require replacement of the native heart valve with an artificial valve. There are a number of known artificial valves and a number of known methods of implanting these artificial valves in humans.
One method of implanting an artificial heart valve in a human patient is via open-chest surgery, during which the patient's heart is stopped and the patient is placed on cardiopulmonary bypass (using a so-called “heart-lung machine”). In one common surgical procedure, the diseased native valve leaflets are excised and a prosthetic valve is sutured to the surrounding tissue at the native valve annulus. Because of the trauma associated with the procedure and the attendant duration of extracorporeal blood circulation, some patients do not survive the surgical procedure or die shortly thereafter. It is well known that the risk to the patient increases with the amount of time required on extracorporeal circulation. Due to these risks, a substantial number of patients with defective native valves are deemed inoperable because their condition is too frail to withstand the procedure.
Because of the drawbacks associated with conventional open-chest surgery, percutaneous and minimally-invasive surgical approaches are in some cases preferred. In one such technique, a prosthetic valve is configured to be implanted in a much less invasive procedure by way of catheterization. For instance, U.S. Pat. Nos. 7,393,360, 7,510,575, and 7,993,394 describe collapsible transcatheter prosthetic heart valves that can be percutaneously introduced in a compressed state on a catheter and expanded to a functional size at the desired position by balloon inflation or by utilization of a self-expanding frame or stent.
In some embodiments, an implantable prosthetic valve comprises a radially collapsible and radially expandable, annular, main body defining a lumen therethrough, a first flange coupled to the main body and extending radially away from the main body, the first flange comprising a plurality of radially extending first protrusions, a second flange coupled to the main body and extending radially away from the main body, the second flange comprising a plurality of radially extending second protrusions, and a valve member supported within the lumen of the frame, wherein the first flange and the second flange are closer to one another when the main body is in a radially expanded configuration than when the main body is in a radially collapsed configuration, and wherein each of the first protrusions and each of the second protrusions comprise a first radial strut coupled to a first node of the main body and extending radially away from the main body, a second radial strut coupled to a second node of the main body and extending radially away from the main body, a first angled strut coupled at an angle to the first radial strut, and a second angled strut coupled at an angle to the second radial strut and coupled to the first angled strut.
In some embodiments, the valve member defines an inlet end and an outlet end of the implantable prosthetic valve, and the first flange and the second flange are coupled to the main body at locations located closer to the inlet end than to the outlet end of the implantable prosthetic valve. In some embodiments, the valve member defines an inlet end and an outlet end of the implantable prosthetic valve, and the first flange and the second flange are coupled to the main body at locations located closer to the outlet end than to the inlet end of the implantable prosthetic valve. In some embodiments, the distance between the first flange and the second flange when the prosthetic valve is in the radially collapsed configuration is larger than the thickness of the native human mitral valve annulus, and the distance between the first flange and the second flange when the prosthetic valve is in the radially expanded configuration is smaller than the thickness of the native human mitral valve annulus. In some embodiments, the first protrusions are angularly offset from the second protrusions.
In some embodiments, the main body has a first end and a second end, and comprises a network of struts interconnected at a plurality of nodes to form a plurality of open cells; the first protrusions are coupled to first nodes of the main body at the first end of the main body; and the second protrusions are coupled to second nodes of the main body, which are displaced toward the second end of the main body from the first end of the main body by the smallest increment available. In some embodiments, the main body has a first end and a second end, and comprises a network of struts interconnected at a plurality of nodes to form a plurality of open cells; the first protrusions are coupled to first nodes of the main body at the first end of the main body; and the second protrusions are coupled to second nodes of the main body, the second nodes being the closest nodes in the network of struts to the first nodes. In some embodiments, the main body has a first end and a second end, and comprises a network of struts interconnected at a plurality of nodes to form a plurality of open cells; the first protrusions are coupled to first nodes of the main body at the first end of the main body; and the second protrusions are coupled to second nodes of the main body, the first nodes and the second nodes being situated in a single circumferential row of open cells.
In some embodiments, the first flange extends radially away from the main body such that an angle between a side of the main body and the first flange is between about 70° and about 110°, and the second flange extends radially away from the main body such that an angle between a side of the main body and the second flange is between about 70° and about 110°. In some embodiments, the first flange extends radially away from the main body such that an angle between a side of the main body and the first flange is between about 80° and about 100°, and the second flange extends radially away from the main body such that an angle between a side of the main body and the second flange is between about 80° and about 100°. In some embodiments, the first flange extends radially away from the main body such that an angle between a side of the main body and the first flange is about 90°, and the second flange extends radially away from the main body such that an angle between a side of the main body and the second flange is about 90°.
In some embodiments, the first flange extends radially away from the main body parallel to the second flange. In some embodiments, the first flange and the second flange extend radially away from the main body in directions converging toward one another such that an angle between the radially extending flanges is less than about 10°. In some embodiments, the first flange and the second flange extend radially away from the main body in directions diverging away from one another such that an angle between the radially extending flanges is less than about 10°.
In some embodiments, a method of implanting a prosthetic apparatus at the native mitral valve region of a heart comprises delivering the prosthetic apparatus to the native mitral valve region within a delivery apparatus, and deploying the prosthetic apparatus from the delivery apparatus, wherein the prosthetic apparatus comprises a main body, a first flange coupled to the main body and extending radially away from the main body perpendicular to a side of the main body, and a second flange coupled to the main body and extending radially away from the main body perpendicular to the side of the main body, and wherein deploying the prosthetic apparatus from the delivery apparatus allows the prosthetic apparatus to radially expand, such that a distance between the first flange and the second flange decreases and the first flange and the second flange pinch a native mitral valve annulus between them.
In some embodiments, the prosthetic apparatus has an inlet end and an outlet end, and the first flange and the second flange are coupled to the main body at locations located closer to the inlet end than to the outlet end of the prosthetic apparatus. In some embodiments, the prosthetic apparatus has an inlet end and an outlet end, and the first flange and the second flange are coupled to the main body at locations located closer to the outlet end than to the inlet end of the prosthetic apparatus. In some embodiments, the main body has a first end and a second end, and comprises a network of struts interconnected at a plurality of nodes to form a plurality of open cells; the first flange is coupled to first nodes of the main body at the first end of the main body; and the second flange is coupled to second nodes of the main body, which are displaced toward the second end of the main body from the first end of the main body by the smallest increment available. In some embodiments, the main body has a first end and a second end, and comprises a network of struts interconnected at a plurality of nodes to form a plurality of open cells; the first flange is coupled to first nodes of the main body at the first end of the main body; and the second flange is coupled to second nodes of the main body, the second nodes being the closest nodes in the network of struts to the first nodes. In some embodiments, the main body has a first end and a second end, and comprises a network of struts interconnected at a plurality of nodes to form a plurality of open cells; the first flange is coupled to first nodes of the main body at the first end of the main body; and the second flange is coupled to second nodes of the main body, the first nodes and the second nodes being situated in a single circumferential row of open cells.
The foregoing and other objects, features, and advantages of the invention will become more apparent from the following detailed description, which proceeds with reference to the accompanying figures.
Frames for Use in Prosthetic Valves
The frames described herein can be used to provide structure to prosthetic valves designed to be implanted within the vasculature of a patient. The frames described herein can be particularly advantageous for use in prosthetic valves to be implanted within a patient's native mitral valve, but can be used in prosthetic valves to be implanted in various other portions of a patient's vasculature (e.g., another native valve of the heart, or various other ducts or orifices of the patient's body). When implanted, the frames described herein can provide structural support to a leaflet structure and/or other components of a prosthetic valve such that the prosthetic valve can function as a replacement for a native valve, allowing fluid to flow in one direction through the prosthetic valve from an inlet end to an outlet end, but not in the other or opposite direction from the outlet end to the inlet end. Details of various prosthetic valve components can be found in U.S. Pat. Nos. 6,730,118, 7,393,360, 7,510,575, and 7,993,394, which are hereby incorporated herein by reference in their entireties.
The frames described herein can be configured to be radially collapsible to a collapsed or crimped state for introduction into the body on a delivery catheter and radially expandable to an expanded state for implanting a prosthetic valve at a desired location in the body (e.g., the native mitral valve). The frames can be made of a plastically-expandable material that permits crimping of the prosthetic valve to a smaller profile for delivery and expansion of the prosthetic valve using an expansion device such as the balloon of a balloon catheter. Suitable plastically-expandable materials that can be used to form the frames include, without limitation, stainless steel, cobalt-chromium, nickel-based alloy (e.g., a nickel-cobalt-chromium alloy), polymers, or combinations thereof. In particular embodiments, the frames are made of a nickel-cobalt-chromium-molybdenum alloy, such as MP35N® alloy (SPS Technologies), which is equivalent to UNS R30035 (covered by ASTM F562-02). MP35N® alloy/UNS R30035 comprises 35% nickel, 35% cobalt, 20% chromium, and 10% molybdenum, by weight. It has been found that the use of MP35N® alloy to form a frame provides superior structural results over stainless steel. In particular, when MP35N® alloy is used as the frame material, less material is needed to achieve the same or better performance in radial and crush force resistance, fatigue resistances, and corrosion resistance. Moreover, since less material is required, the crimped profile of the frames can be reduced, thereby providing a lower profile prosthetic valve assembly for percutaneous delivery to the treatment location in the patient's body.
Alternatively, any of the frames described herein can be a so-called self-expanding frame wherein the frame is made of a self-expanding material such as nitinol. A prosthetic valve incorporating a self-expanding frame can be crimped to a smaller profile and held in the crimped state with a restraining device such as a sheath covering the prosthetic valve. When the prosthetic valve is positioned at or near a target site within the patient's vasculature, the restraining device can be removed to allow the prosthetic valve to self-expand to its expanded, functional size.
In an alternative embodiment, the first end portion 118 is a ventricular, outlet end portion, the second end portion 120 is an atrial, inlet end portion, the first flange 104 is a ventricular flange, and the second flange 106 is an atrial flange 106.
The main body 102 and flanges 104, 106 have generally circular shapes in the illustrated embodiment. In alternative embodiments, the main body and flanges of a prosthetic mitral valve frame can have non-circular shapes, for example, to accommodate the non-circular shape of the native mitral valve annulus. In certain embodiments, the main body and flanges of a prosthetic mitral valve frame can be generally oval-shaped, ellipse-shaped, kidney-shaped, or D-shaped.
In the illustrated embodiment, the atrial flange 104 and the ventricular flange 106 are coupled to the main body 102 at respective locations located nearer to the atrial end 118 of the main body 102 than to the ventricular end 120. More specifically, the atrial flange 104 is coupled to the nodes 110A of the main body 102 which are closest to the atrial end portion 118 of the main body 102. The ventricular flange 106 is coupled to the nodes 110B of the main body 102 which are displaced toward the ventricular end 120 of the main body 102 from the atrial flange 104 by the smallest increment available. That is, the nodes 110B are the closest nodes 110 in the network of struts 108 to the nodes 110A. In other embodiments, the nodes 110B are not the closest nodes 110 to the nodes 110A, for example, the second closest or third closest nodes, or another set of nodes. In alternative embodiments, the atrial and ventricular flanges 104, 106 can be coupled to the main body 102 at any suitable locations, which need not be at nodes 110. For example, one or both of the flanges 104, 106 can be coupled to the mid-points of struts 108 of the main body 102 rather than to nodes 110.
As shown in
Each ventricular protrusion 124 similarly comprises a first radial strut 140 coupled to a node 110B (
The nodes 138 and 152 of the protrusions 122 and 124, respectively, comprise generally U-shaped crown structures or crown portions. Crown structures can each include a horizontal portion extending between and connecting the adjacent ends of the struts such that a gap is defined between the adjacent ends and the crown structure connects the adjacent ends at a location offset from the struts' natural point of intersection. The nodes 132 and 136, and 146 and 150 of the protrusions 122 and 124, respectively, also comprise stepped portions that are shaped to connect the adjacent ends of the struts at a location offset from the struts' natural point of intersection. Crown structures and stepped portions, both individually and in combination, can significantly reduce strain on the frame 100 during crimping and expanding of the frame 100. Further details regarding crown structures are available in U.S. Pat. No. 7,993,394.
Also shown in
In the illustrated embodiment, the commissure attachment posts 114 are coupled to radial struts 140, 142 of ventricular protrusions 124, but not to radial struts 126, 128 of atrial protrusions 122. Also in the illustrated embodiment, the commissure attachment posts 114 are angularly aligned about a central longitudinal axis of the frame 100 with radial nodes 138 of atrial protrusions 122, but not with radial nodes 152 of ventricular protrusions 124. In alternative embodiments, the commissure attachment posts 114 can be coupled to radial struts 126, 128 of atrial protrusions 122, and angularly aligned about the central longitudinal axis with radial nodes 152 of ventricular protrusions 124.
As explained above, a prosthetic valve frame can be radially collapsible to a collapsed or crimped state for introduction into the body, and radially expandable to an expanded state for implantation at a desired location in the body.
In some embodiments, S1 can be between about 2 mm and about 20 mm, with about 6 mm being one possible specific dimension. In some embodiments, S2 can be between about 4 mm and about 30 mm, with about 12 mm being one possible specific dimension. In some embodiments, W1 can be between about 30 mm and about 75 mm, with about 55 mm being one possible specific dimension. In some embodiments, W2 can be between about 10 mm and about 60 mm, with about 45 mm being one possible specific dimension. In some embodiments, D1 can be between about 25 mm and about 50 mm, with about 29 mm being one possible specific dimension. In some embodiments, D2 can be between about 4 mm and about 10 mm, with about 6.5 mm being one possible specific dimension.
As illustrated in
As shown in
The frame 200 can be used as the frame of a prosthetic valve to be implanted at the native mitral valve of a human heart. As shown in
This method takes advantage of the relative movement of the nodes of the prosthetic valve frame in a direction aligned with the central longitudinal axis of the prosthetic valve. In particular, as a prosthetic valve frame such as frame 100 or frame 200 is radially expanded, nodes aligned with one another along an axis parallel to the central longitudinal axis move toward one another. Thus, by coupling a pair of flanges such as flanges 104 and 106, or flanges 204 and 206 to nodes spaced apart from each other axially, the flanges can be made to approach one another as the prosthetic valve expands.
Delivery Systems and Methods
As shown in
In an alternative embodiment, the protrusions of a flange of a prosthetic valve frame, such as the protrusions of flanges 104, 106, 204, or 206, or protrusions 422 of prosthetic valve frame 420, can fit within or extend through the distal slots 408 of the slotted sheath 404. As described above, as prosthetic valve frames 100, 200, 420 are compressed to a crimped configuration, the respective protrusions are compressed angularly such that they transition from a series of relatively wide and short, radially-extending protrusions to a series of relatively narrow and long, radially-extending protrusions. Thus, the protrusions can be configured to fit within the distal slots 408 when a frame is in the crimped configuration. In this embodiment, loading a prosthetic valve into a delivery system can include crimping the prosthetic valve to a compressed configuration, inserting the compressed prosthetic valve into the slotted sheath 404 such that the angularly compressed protrusions fit within the distal slots 408 of the slotted sheath 404, and then adjusting the protrusions so they lie flat against the outside of the slotted sheath 404, or so they lie flat within the slots 408 and against the outside of the main body of the prosthetic valve, so the prosthetic valve and slotted sheath 404 can be contained within the outer sheath 402 and recess 414 of the nosecone 410. The protrusions of one of the flanges can be contained within the nosecone 410, and the protrusions of the other flange can be contained within the outer sheath 402. Adjusting the protrusions so they lie flat against the outside of the slotted sheath, or so they lie flat within the slots 408 and against the outside of the main body of the prosthetic valve, can include bending the protrusions of the atrial flange so they point either toward or away from the protrusions of the ventricular flange, and bending the protrusions of the ventricular flange so they point either toward or away from the protrusions of the atrial flange.
Loading a prosthetic valve including a frame such as frame 100, frame 200, or frame 420 into the delivery system can proceed according to similar methods, but is described herein with reference to frame 420 for convenience. Loading a prosthetic valve including frame 420 into the delivery system can include crimping the prosthetic valve to a compressed configuration, in which the protrusions 422A, 422B of the frame are angularly compressed, as described above. The compressed prosthetic valve can then be inserted into the slotted sheath 500 such that the angularly compressed protrusions 422A, 422B fit within slots 507 between the extensions 506, such that the protrusions 422A are proximal to the protrusions 422B, and such that the proximal set of angularly compressed protrusions 422A extend through the slots 507 and the openings 516. The retaining element 510 can then be rotated in the opposite direction shown by arrow 518, so as to pinch the proximal set of angularly compressed protrusions 422A between the teeth 512 and the extensions 506. The angularly compressed protrusions 422A and 422B can then be adjusted so they lie flat against the outside of the slotted sheath 500, or so they lie flat within the slots 507 and against the outside of the main body 424 of the prosthetic valve frame 420. The outer sheath 502 can then be actuated to move distally with respect to the slotted sheath 500 to enclose the slotted sheath 500, the retaining element 510, and the prosthetic valve.
Deployment of the prosthetic valve from the delivery system can generally progress as described above with reference to
The retaining element 510 can provide substantial benefits to the delivery system. For example, the retaining element 510 can help to restrain the distal extensions 506 against radial expansion from the expansion force of the prosthetic valve retained within the extensions 506. In particular, as the prosthetic valve moves distally through the extensions 506, the extensions 506 can tend to splay farther and farther apart. The retaining element can help to reduce this effect by maintaining a ring of material (e.g., the distal end portion of the sheath 511) in proximity to the proximal end of the prosthetic valve as the prosthetic valve moves through the extensions 506. This can provide an operator with a greater degree of control over the delivery system and the deployment of the prosthetic valve therefrom.
Loading a prosthetic valve including a frame such as frame 100 or frame 200 into the delivery system can generally progress as described above, and such that a proximal set of angularly compressed protrusions 422A of a prosthetic valve frame fit within the openings 526. The retaining element 520 can be rotated in the opposite direction shown by arrow 528 so as to capture the proximal set of angularly compressed protrusions 422A in the enclosed openings 526. Deployment of the prosthetic valve from the delivery system can generally progress as described above. When the prosthetic valve approaches the distal end of the extensions 506, the retaining element 520 can be rotated in the direction shown by the arrow 528 such that it no longer captures or constrains (e.g., it releases) the proximal protrusions 422A.
The retaining element 520 can provide substantial benefits to the delivery system, as described above with regard to retaining element 510. In some cases, the retaining element 510 can be easier to manufacture than the retaining element 520. In some cases, the retaining element 520 provides better performance than the retaining element 510 because the teeth form enclosed openings and capture the proximal protrusions rather than pinching the proximal protrusions.
Delivery Approaches
In some embodiments, a prosthetic valve including protrusions fitted within the distal slots of a slotted sheath such as slotted sheath 404 can be deployed from a delivery system incorporating a retaining element such as retaining element 504, retaining element 510, or retaining element 520, approaching the native mitral valve from the ventricular side of the native mitral valve annulus 308. The prosthetic valve can be compressed to a crimped configuration and loaded into the delivery system such that the protrusions of an atrial flange are retained within the nosecone 410 of the delivery system and the protrusions of a ventricular flange are retained within the outer sheath 402 of the delivery system. The delivery system can then advance the prosthetic valve to the native mitral valve from the ventricular side of the native mitral valve annulus via either a transventricular or a transfemoral approach. In the transventricular approach, the delivery system desirably is inserted through a surgical incision made on the bare spot on the lower anterior ventricle wall.
As shown in
In some embodiments, a prosthetic valve including protrusions fitted within the distal slots of a slotted sheath such as slotted sheath 404 can be deployed from a delivery system incorporating a retaining element such as retaining element 504, retaining element 510, or retaining element 520, approaching the native mitral valve from the atrial side of the native mitral valve annulus 308. The prosthetic valve can be compressed to a crimped configuration and loaded into the delivery system such that the protrusions 124 of a ventricular flange 106 are retained within the nosecone 410 of the delivery system and the protrusions 122 of an atrial flange 104 are retained within the outer sheath 402 of the delivery system. The delivery system can then advance the prosthetic valve to the native mitral valve from the atrial side of the native mitral valve annulus via either a transeptal or a transatrial approach.
The nosecone 410 can then be extended to deploy the protrusions 124 of the ventricular flange 106 within the left ventricle 304, and the delivery system can be retracted until the ventricular flange 106 is in contact with the native valve leaflets 306 and adjacent the ventricular side of the native mitral valve annulus 308. The outer sheath 402 can then be retracted to deploy the protrusions 122 of the atrial flange 104 into the left atrium 302, across the native mitral valve annulus 308 from the protrusions of the ventricular flange 106. In cases where retaining element 504 (
In embodiments in which protrusions of the frame of a prosthetic valve extend through the distal slots 408 of the slotted sheath 404, the angular compression of the protrusions makes them narrower, and thus easier to navigate to the native mitral valve. For example, the native mitral valve can include chordae tendineae 310 (
For purposes of this description, certain aspects, advantages, and novel features of the embodiments of this disclosure are described herein. The disclosed methods, apparatuses, and systems should not be construed as limiting in any way. Instead, the present disclosure is directed toward all novel and nonobvious features and aspects of the various disclosed embodiments, alone and in various combinations and sub-combinations with one another. The methods, apparatuses, and systems are not limited to any specific aspect or feature or combination thereof, nor do the disclosed embodiments require that any one or more specific advantages be present or problems be solved.
Although the operations of some of the disclosed methods are described in a particular, sequential order for convenient presentation, it should be understood that this manner of description encompasses rearrangement, unless a particular ordering is required by specific language. For example, operations described sequentially may in some cases be rearranged or performed concurrently. Moreover, for the sake of simplicity, the attached figures may not show the various ways in which the disclosed methods can be used in conjunction with other methods. As used herein, the terms “a”, “an” and “at least one” encompass one or more of the specified element. That is, if two of a particular element are present, one of these elements is also present and thus “an” element is present. The terms “a plurality of” and “plural” mean two or more of the specified element.
As used herein, the term “and/or” used between the last two of a list of elements means any one or more of the listed elements. For example, the phrase “A, B, and/or C” means “A”, “B”, “C”, “A and B”, “A and C”, “B and C”, or “A, B and C.” As used herein, the term “coupled” generally means physically coupled or linked and does not exclude the presence of intermediate elements between the coupled items absent specific contrary language.
In view of the many possible embodiments to which the principles of the disclosed invention may be applied, it should be recognized that the illustrated embodiments are only preferred examples of the invention and should not be taken as limiting the scope of the invention. Rather, the scope of the invention is defined by the following claims. We therefore claim as our invention all that comes within the scope and spirit of these claims.
The present application is a continuation of U.S. application Ser. No. 16/104,015, filed Aug. 16, 2018, now U.S. Pat. No. 10,881,512, which is a continuation of U.S. application Ser. No. 14/830,347, filed Aug. 19, 2015, now U.S. Pat. No. 10,058,424, which claims the benefit of U.S. Provisional Application No. 62/040,099, filed Aug. 21, 2014, which is incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
3409013 | Berry | Nov 1968 | A |
3472230 | Fogarty | Oct 1969 | A |
3548417 | Kisher | Dec 1970 | A |
3587115 | Shiley | Jun 1971 | A |
3657744 | Ersek | Apr 1972 | A |
3671979 | Moulopoulos | Jun 1972 | A |
3714671 | Edwards et al. | Feb 1973 | A |
3755823 | Hancock | Sep 1973 | A |
4035849 | Angell et al. | Jul 1977 | A |
4056854 | Boretos et al. | Nov 1977 | A |
4106129 | Carpentier et al. | Aug 1978 | A |
4222126 | Boretos et al. | Sep 1980 | A |
4265694 | Boretos et al. | May 1981 | A |
4297749 | Davis et al. | Nov 1981 | A |
4339831 | Johnson | Jul 1982 | A |
4343048 | Ross et al. | Aug 1982 | A |
4345340 | Rosen | Aug 1982 | A |
4373216 | Klawitter | Feb 1983 | A |
4406022 | Roy | Sep 1983 | A |
4470157 | Love | Sep 1984 | A |
4535483 | Klawitter et al. | Aug 1985 | A |
4574803 | Storz | Mar 1986 | A |
4592340 | Boyles | Jun 1986 | A |
4605407 | Black et al. | Aug 1986 | A |
4612011 | Kautzky | Sep 1986 | A |
4643732 | Pietsch et al. | Feb 1987 | A |
4655771 | Wallsten | Apr 1987 | A |
4692164 | Dzemeshkevich et al. | Sep 1987 | A |
4733665 | Palmaz | Mar 1988 | A |
4759758 | Gabbay | Jul 1988 | A |
4762128 | Rosenbluth | Aug 1988 | A |
4777951 | Cribier et al. | Oct 1988 | A |
4787899 | Lazarus | Nov 1988 | A |
4787901 | Baykut | Nov 1988 | A |
4796629 | Grayzel | Jan 1989 | A |
4829990 | Thuroff et al. | May 1989 | A |
4851001 | Taheri | Jul 1989 | A |
4856516 | Hillstead | Aug 1989 | A |
4878495 | Grayzel | Nov 1989 | A |
4878906 | Lindemann et al. | Nov 1989 | A |
4883458 | Shiber | Nov 1989 | A |
4922905 | Strecker | May 1990 | A |
4966604 | Reiss | Oct 1990 | A |
4979939 | Shiber | Dec 1990 | A |
4986830 | Owens et al. | Jan 1991 | A |
4994077 | Dobben | Feb 1991 | A |
5007896 | Shiber | Apr 1991 | A |
5026366 | Leckrone | Jun 1991 | A |
5032128 | Alonso | Jul 1991 | A |
5037434 | Lane | Aug 1991 | A |
5047041 | Samuels | Sep 1991 | A |
5059177 | Towne et al. | Oct 1991 | A |
5080668 | Bolz et al. | Jan 1992 | A |
5085635 | Cragg | Feb 1992 | A |
5089015 | Ross | Feb 1992 | A |
5108370 | Walinsky | Apr 1992 | A |
5152771 | Sabbaghian et al. | Oct 1992 | A |
5163953 | Vince | Nov 1992 | A |
5167628 | Boyles | Dec 1992 | A |
5192297 | Hull | Mar 1993 | A |
5232446 | Arney | Aug 1993 | A |
5266073 | Wall | Nov 1993 | A |
5282847 | Trescony et al. | Feb 1994 | A |
5295958 | Shturman | Mar 1994 | A |
5332402 | Teitelbaum | Jul 1994 | A |
5360444 | Kusuhara | Nov 1994 | A |
5370685 | Stevens | Dec 1994 | A |
5397351 | Pavcnik et al. | Mar 1995 | A |
5411055 | Kane | May 1995 | A |
5411522 | Trott | May 1995 | A |
5411552 | Andersen et al. | May 1995 | A |
5443446 | Shturman | Aug 1995 | A |
5480424 | Cox | Jan 1996 | A |
5500014 | Quijano et al. | Mar 1996 | A |
5545209 | Roberts et al. | Aug 1996 | A |
5545214 | Stevens | Aug 1996 | A |
5549665 | Vesely et al. | Aug 1996 | A |
5554185 | Block et al. | Sep 1996 | A |
5571175 | Vanney et al. | Nov 1996 | A |
5591185 | Kilmer et al. | Jan 1997 | A |
5599305 | Hermann et al. | Feb 1997 | A |
5607464 | Trescony et al. | Mar 1997 | A |
5609626 | Quijano et al. | Mar 1997 | A |
5639274 | Fischell et al. | Jun 1997 | A |
5665115 | Cragg | Sep 1997 | A |
5716417 | Girard et al. | Feb 1998 | A |
5728068 | Leone et al. | Mar 1998 | A |
5749890 | Shaknovich | May 1998 | A |
5756476 | Epstein et al. | May 1998 | A |
5769812 | Stevens et al. | Jun 1998 | A |
5800508 | Goicoechea et al. | Sep 1998 | A |
5840081 | Andersen et al. | Nov 1998 | A |
5855597 | Jayaraman | Jan 1999 | A |
5855601 | Bessler et al. | Jan 1999 | A |
5855602 | Angell | Jan 1999 | A |
5906619 | Olson et al. | May 1999 | A |
5925063 | Khosravi | Jul 1999 | A |
5957949 | Leonhardt et al. | Sep 1999 | A |
5968068 | Dehdashtian et al. | Oct 1999 | A |
6027525 | Suh et al. | Feb 2000 | A |
6042607 | Williamson, IV et al. | Mar 2000 | A |
6132473 | Williams et al. | Oct 2000 | A |
6168614 | Andersen et al. | Jan 2001 | B1 |
6171335 | Wheatley et al. | Jan 2001 | B1 |
6174327 | Mertens et al. | Jan 2001 | B1 |
6210408 | Chandrasekaran et al. | Apr 2001 | B1 |
6217585 | Houser et al. | Apr 2001 | B1 |
6221091 | Khosravi | Apr 2001 | B1 |
6231602 | Carpentier et al. | May 2001 | B1 |
6245040 | Inderbitzen et al. | Jun 2001 | B1 |
6245102 | Jayaraman | Jun 2001 | B1 |
6287339 | Vazquez et al. | Sep 2001 | B1 |
6299637 | Shaolian et al. | Oct 2001 | B1 |
6302906 | Goecoechea et al. | Oct 2001 | B1 |
6306141 | Jervis | Oct 2001 | B1 |
6312465 | Griffin et al. | Nov 2001 | B1 |
6350277 | Kocur | Feb 2002 | B1 |
6379372 | Dehdashtian et al. | Apr 2002 | B1 |
6425916 | Garrison et al. | Jul 2002 | B1 |
6440164 | Di Matteo et al. | Aug 2002 | B1 |
6454799 | Schreck | Sep 2002 | B1 |
6458153 | Bailey et al. | Oct 2002 | B1 |
6461382 | Cao | Oct 2002 | B1 |
6468660 | Ogle et al. | Oct 2002 | B2 |
6482228 | Norred | Nov 2002 | B1 |
6488704 | Connelly et al. | Dec 2002 | B1 |
6527979 | Constantz | Mar 2003 | B2 |
6569196 | Vesely | May 2003 | B1 |
6575959 | Sarge et al. | Jun 2003 | B1 |
6582462 | Andersen et al. | Jun 2003 | B1 |
6605112 | Moll et al. | Aug 2003 | B1 |
6730118 | Spenser et al. | May 2004 | B2 |
6733525 | Yang et al. | May 2004 | B2 |
6790229 | Berreklouw | Sep 2004 | B1 |
6830584 | Seguin | Dec 2004 | B1 |
6893460 | Spenser et al. | May 2005 | B2 |
6908481 | Cribier | Jun 2005 | B2 |
6974476 | McGuckin, Jr. et al. | Dec 2005 | B2 |
7018406 | Seguin et al. | Mar 2006 | B2 |
7198646 | Figulla et al. | Apr 2007 | B2 |
7201772 | Schwammenthal et al. | Apr 2007 | B2 |
7276078 | Spenser et al. | Oct 2007 | B2 |
7276084 | Yang et al. | Oct 2007 | B2 |
7318278 | Zhang et al. | Jan 2008 | B2 |
7338520 | Bailey et al. | Mar 2008 | B2 |
7374571 | Pease et al. | May 2008 | B2 |
7381210 | Zarbatany et al. | Jun 2008 | B2 |
7393360 | Spenser et al. | Jul 2008 | B2 |
7429269 | Schwammenthal et al. | Sep 2008 | B2 |
7442204 | Schwammenthal et al. | Oct 2008 | B2 |
7462191 | Spenser et al. | Dec 2008 | B2 |
7524330 | Berreklouw | Apr 2009 | B2 |
7530253 | Spenser et al. | May 2009 | B2 |
7579381 | Dove | Aug 2009 | B2 |
7585321 | Cribier | Sep 2009 | B2 |
7618446 | Andersen et al. | Nov 2009 | B2 |
7621948 | Herrmann et al. | Nov 2009 | B2 |
7704222 | Wilk et al. | Apr 2010 | B2 |
7736327 | Wilk et al. | Jun 2010 | B2 |
7892281 | Seguin et al. | Feb 2011 | B2 |
7914575 | Guyenot et al. | Mar 2011 | B2 |
7993394 | Hariton et al. | Aug 2011 | B2 |
8007992 | Tian et al. | Aug 2011 | B2 |
8029556 | Rowe | Oct 2011 | B2 |
8092521 | Figulla et al. | Jan 2012 | B2 |
8118866 | Herrmann et al. | Feb 2012 | B2 |
8167932 | Bourang | May 2012 | B2 |
8206437 | Bonhoeffer et al. | Jun 2012 | B2 |
8216174 | Wilk et al. | Jul 2012 | B2 |
8317858 | Straubinger et al. | Nov 2012 | B2 |
8398704 | Straubinger et al. | Mar 2013 | B2 |
8416643 | Magee | Apr 2013 | B2 |
8449599 | Chau et al. | May 2013 | B2 |
8460370 | Zakay | Jun 2013 | B2 |
8579964 | Lane et al. | Nov 2013 | B2 |
9173737 | Hill et al. | Nov 2015 | B2 |
9393111 | Ma et al. | Jul 2016 | B2 |
20010021872 | Bailey et al. | Sep 2001 | A1 |
20020032481 | Gabbay | Mar 2002 | A1 |
20020173842 | Buchanan | Nov 2002 | A1 |
20030023300 | Bailey et al. | Jan 2003 | A1 |
20030050694 | Yang et al. | Mar 2003 | A1 |
20030100939 | Yodfat et al. | May 2003 | A1 |
20030158597 | Quiachon et al. | Aug 2003 | A1 |
20030212454 | Scott et al. | Nov 2003 | A1 |
20040039436 | Spenser et al. | Feb 2004 | A1 |
20040092858 | Wilson et al. | May 2004 | A1 |
20040133263 | Dusbabek et al. | Jul 2004 | A1 |
20040186563 | Lobbi | Sep 2004 | A1 |
20040186565 | Schreck | Sep 2004 | A1 |
20040260389 | Case et al. | Dec 2004 | A1 |
20050137688 | Salahieh et al. | Jun 2005 | A1 |
20050137690 | Salahieh et al. | Jun 2005 | A1 |
20050137698 | Salahieh et al. | Jun 2005 | A1 |
20050203617 | Forster et al. | Sep 2005 | A1 |
20050234546 | Nugent et al. | Oct 2005 | A1 |
20050288766 | Plain et al. | Dec 2005 | A1 |
20060025857 | Bergheim et al. | Feb 2006 | A1 |
20060058872 | Salahieh et al. | Mar 2006 | A1 |
20060142837 | Haverkost et al. | Jun 2006 | A1 |
20060149350 | Patel et al. | Jul 2006 | A1 |
20060161249 | Realyvasquez et al. | Jul 2006 | A1 |
20060195134 | Crittenden | Aug 2006 | A1 |
20060229719 | Marquez et al. | Oct 2006 | A1 |
20060241745 | Solem | Oct 2006 | A1 |
20060259135 | Navia et al. | Nov 2006 | A1 |
20060259137 | Artof et al. | Nov 2006 | A1 |
20060276874 | Wilson et al. | Dec 2006 | A1 |
20070005131 | Taylor | Jan 2007 | A1 |
20070010877 | Salahieh et al. | Jan 2007 | A1 |
20070027534 | Bergheim et al. | Feb 2007 | A1 |
20070066863 | Rafiee et al. | Mar 2007 | A1 |
20070088431 | Bourang et al. | Apr 2007 | A1 |
20070100439 | Cangialosi et al. | May 2007 | A1 |
20070112422 | Dehdashtian | May 2007 | A1 |
20070142906 | Figulla et al. | Jun 2007 | A1 |
20070156224 | Cioanta et al. | Jul 2007 | A1 |
20070203503 | Salahieh et al. | Aug 2007 | A1 |
20070203575 | Forster et al. | Aug 2007 | A1 |
20070213813 | Von Segesser et al. | Sep 2007 | A1 |
20070270943 | Solem et al. | Nov 2007 | A1 |
20080065011 | Marchand et al. | Mar 2008 | A1 |
20080071361 | Tuval et al. | Mar 2008 | A1 |
20080071362 | Tuval et al. | Mar 2008 | A1 |
20080071363 | Tuval et al. | Mar 2008 | A1 |
20080071366 | Tuval et al. | Mar 2008 | A1 |
20080071368 | Tuval et al. | Mar 2008 | A1 |
20080071369 | Tuval et al. | Mar 2008 | A1 |
20080082166 | Styrc et al. | Apr 2008 | A1 |
20080114442 | Mitchell et al. | May 2008 | A1 |
20080125853 | Bailey et al. | May 2008 | A1 |
20080154355 | Benichou et al. | Jun 2008 | A1 |
20080161911 | Revuelta et al. | Jul 2008 | A1 |
20080208328 | Antocci et al. | Aug 2008 | A1 |
20080208332 | Lamphere et al. | Aug 2008 | A1 |
20080221672 | Lamphere et al. | Sep 2008 | A1 |
20080255660 | Guyenot et al. | Oct 2008 | A1 |
20080255661 | Straubinger et al. | Oct 2008 | A1 |
20080281411 | Berreklouw | Nov 2008 | A1 |
20090005863 | Goetz et al. | Jan 2009 | A1 |
20090054968 | Bonhoeffer et al. | Feb 2009 | A1 |
20090054974 | McGuckin, Jr. et al. | Feb 2009 | A1 |
20090076598 | Salahieh et al. | Mar 2009 | A1 |
20090112309 | Jaramillo et al. | Apr 2009 | A1 |
20090138079 | Tuval et al. | May 2009 | A1 |
20090157175 | Benichou | Jun 2009 | A1 |
20090164005 | Dove et al. | Jun 2009 | A1 |
20090171432 | Von Segesser et al. | Jul 2009 | A1 |
20090171447 | Von Segesser et al. | Jul 2009 | A1 |
20090171456 | Kveen et al. | Jul 2009 | A1 |
20090216310 | Straubinger et al. | Aug 2009 | A1 |
20090216313 | Straubinger et al. | Aug 2009 | A1 |
20090216322 | Le et al. | Aug 2009 | A1 |
20090222076 | Figulla et al. | Sep 2009 | A1 |
20090234443 | Ottma et al. | Sep 2009 | A1 |
20090240320 | Tuval et al. | Sep 2009 | A1 |
20090276040 | Rowe et al. | Nov 2009 | A1 |
20090281619 | Le et al. | Nov 2009 | A1 |
20090287299 | Tabor et al. | Nov 2009 | A1 |
20090292350 | Eberhardt | Nov 2009 | A1 |
20090319037 | Rowe et al. | Dec 2009 | A1 |
20100016958 | St. Goar et al. | Jan 2010 | A1 |
20100036479 | Hill et al. | Feb 2010 | A1 |
20100049313 | Alon et al. | Feb 2010 | A1 |
20100131054 | Tuval et al. | May 2010 | A1 |
20100137979 | Tuval et al. | Jun 2010 | A1 |
20100174362 | Straubinger et al. | Jul 2010 | A1 |
20100204781 | Alkhatib | Aug 2010 | A1 |
20100217382 | Chau et al. | Aug 2010 | A1 |
20100262231 | Tuval et al. | Oct 2010 | A1 |
20110015616 | Straubinger et al. | Jan 2011 | A1 |
20110015729 | Jimenez et al. | Jan 2011 | A1 |
20110029072 | Gabbay | Feb 2011 | A1 |
20110137397 | Chau et al. | Jun 2011 | A1 |
20110208290 | Straubinger et al. | Aug 2011 | A1 |
20110208297 | Tuval et al. | Aug 2011 | A1 |
20110208298 | Tuval et al. | Aug 2011 | A1 |
20110238159 | Guyenot et al. | Sep 2011 | A1 |
20110288634 | Tuval et al. | Nov 2011 | A1 |
20110319989 | Lane et al. | Dec 2011 | A1 |
20120035722 | Tuval | Feb 2012 | A1 |
20120046741 | Tuval et al. | Feb 2012 | A1 |
20120046742 | Tuval et al. | Feb 2012 | A1 |
20120101570 | Tuval et al. | Apr 2012 | A1 |
20120123529 | Levi et al. | May 2012 | A1 |
20120185039 | Tuval et al. | Jul 2012 | A1 |
20120197386 | Von Segesser et al. | Aug 2012 | A1 |
20120209374 | Bonhoeffer et al. | Aug 2012 | A1 |
20120283823 | Bonhoeffer et al. | Nov 2012 | A1 |
20120296418 | Bonyuet et al. | Nov 2012 | A1 |
20120310336 | Figulla et al. | Dec 2012 | A1 |
20130035759 | Gross et al. | Feb 2013 | A1 |
20130073035 | Tuval et al. | Mar 2013 | A1 |
20130079869 | Straubinger et al. | Mar 2013 | A1 |
20130144381 | Quadri et al. | Jun 2013 | A1 |
20130190862 | Pintor et al. | Jul 2013 | A1 |
20130197622 | Mitra et al. | Aug 2013 | A1 |
20140194979 | Seguin et al. | Jul 2014 | A1 |
20140277390 | Ratz et al. | Sep 2014 | A1 |
20140330371 | Gloss et al. | Nov 2014 | A1 |
Number | Date | Country |
---|---|---|
2246526 | Mar 1973 | DE |
19532846 | Mar 1997 | DE |
19546692 | Jun 1997 | DE |
19857887 | Jul 2000 | DE |
19907646 | Aug 2000 | DE |
10010074 | Oct 2001 | DE |
10049812 | Apr 2002 | DE |
10049813 | Apr 2002 | DE |
10049814 | Apr 2002 | DE |
10049815 | Apr 2002 | DE |
102006052564 | Dec 2007 | DE |
0103546 | Mar 1984 | EP |
0144167 | Jun 1985 | EP |
0592410 | Apr 1994 | EP |
0597967 | May 1994 | EP |
0850607 | Jul 1998 | EP |
1057460 | Dec 2000 | EP |
1088529 | Apr 2001 | EP |
1469797 | Oct 2004 | EP |
1570809 | Sep 2005 | EP |
1653888 | May 2006 | EP |
3294221 | Mar 2018 | EP |
2788217 | Jul 2000 | FR |
2815844 | May 2002 | FR |
2056023 | Mar 1981 | GB |
1271508 | Nov 1986 | SU |
9117720 | Nov 1991 | WO |
9217118 | Oct 1992 | WO |
93001768 | Feb 1993 | WO |
9724080 | Jul 1997 | WO |
9829057 | Jul 1998 | WO |
9933414 | Jul 1999 | WO |
9940964 | Aug 1999 | WO |
9947075 | Sep 1999 | WO |
0018333 | Apr 2000 | WO |
0041652 | Jul 2000 | WO |
0047139 | Aug 2000 | WO |
0128459 | Apr 2001 | WO |
0135878 | May 2001 | WO |
0149213 | Jul 2001 | WO |
0154624 | Aug 2001 | WO |
0154625 | Aug 2001 | WO |
0162189 | Aug 2001 | WO |
0164137 | Sep 2001 | WO |
0176510 | Oct 2001 | WO |
0222054 | Mar 2002 | WO |
0236048 | May 2002 | WO |
0241789 | May 2002 | WO |
0243620 | Jun 2002 | WO |
0247575 | Jun 2002 | WO |
0249540 | Jun 2002 | WO |
03047468 | Jun 2003 | WO |
2005034812 | Apr 2005 | WO |
2005087140 | Sep 2005 | WO |
2006014233 | Feb 2006 | WO |
2006034008 | Mar 2006 | WO |
06108090 | Oct 2006 | WO |
2006111391 | Oct 2006 | WO |
2006138173 | Dec 2006 | WO |
2005102015 | Apr 2007 | WO |
2008005405 | Jan 2008 | WO |
2008035337 | Mar 2008 | WO |
2008147964 | Dec 2008 | WO |
2008150529 | Dec 2008 | WO |
09024859 | Feb 2009 | WO |
09116041 | Sep 2009 | WO |
2010127041 | Nov 2010 | WO |
Entry |
---|
Al-Khaja, N., et al., “Eleven Years' Experience with Carpentier-Edwards Biological Valves in Relation to Survival and Complications,” European Journal of Cardiothoracic Surgery 3:305-311, Jun. 30, 2009. |
Almagor, M.D., Yaron, et al., “Balloon Expandable Stent Implantation in Stenotic Right Heart Valved Conduits,” Journal of the American College of Cardiology, vol. 16, No. 6, pp. 1310-1314, Nov. 1, 1990; ISSN 0735-1097. |
Al Zaibag, Muayed, et al., “Percutaneous Balloon Valvotomy in Tricuspid Stenosis,” British Heart Journal, Jan. 1987, vol. 57, No. 1, pp. 51-53. |
Andersen, et al., “Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs.” European Heart Journal (1992), 13, 704-708. |
Andersen, Henning Rud, “History of Percutaneous Aortic Valve Prosthesis,” Herz 34 2009 Nr. 5, Urban & Vogel, pp. 343-346, Skejby University Hospital Department of Cardiology, Aarhus, Denmark. |
Benchimol, Alberto, et al., “Simultaneous Left Ventricular Echocardiography and Aortic Blood Velocity During Rapid Right Ventricular Pacing in Man,” The American Journal of the Medical Sciences, Jan.-Feb. 1977 vol. 273, No. 1, pp. 55-62. |
Dake, Transluminal Placement of Endovascular Stent-Grafts for the Treatment of Descending Thoracic Aortic Aneurysms, New Engl.J.Med., 1994; 331:1729 34. |
Dotter, M.D., Charles T., “Transluminal Treatment of Arteriosclerotic Obstruction,” University of Oregon's Minthorn Memorial Laboratory for Cardiovascular Research through Radiology, Circulation, vol. XXX, Nov. 1964, pp. 654-670. |
Kolata, Gina, “Device That Opens Clogged Arteries Gets a Failing Grade in a New Study,” nytimes.com, http://www.nytimes.com/1991/01/03/health/device-that-opens-clogged-arteries-gets-a-faili . . . , Jul. 29, 2009, 2 pages. |
Inoue, M.D., Kanji, et al., “Clinical Application of Transvenous Mitral Commissurotomy by a New Balloon Catheter,” The Journal of Thoracic and Cardiovascular Surgery 87:394-402, 1984. |
Lawrence, Jr., M.D., David D., “Percutaneous Endovascular Graft: Experimental Evaluation,” Radiology 1897; 163: 357-360. |
Pavcnik, M.D., Ph.D., Dusan, et al. “Development and Initial Experimental Evaluation of a Prosthetic Aortic Valve for Transcatheter Placement,” Cardiovascular Radiology 1992; 183:151-154. |
Porstmann, W., et al., “Der Verschluß des Ductus Arteriosus Persistens ohne Thorakotomie,” Thoraxchirurgie Vaskuläre Chirurgie, Band 15, Heft 2, Stuttgart, im Apr. 1967, pp. 199-203. |
Rashkind, M.D., William J., “Creation of an Atrial Septal Defect Withoput Thoracotomy,” the Journal of the American Medical Association, vol. 196, No. 11, Jun. 13, 1966, pp. 173-174. |
Rashkind, M.D., William J., “Historical Aspects of Interventional Cardiology: Past, Present, Future,” Texas Heart Institute Journal, Interventional Cardiology, pp. 363-367. |
Rösch, M.D., Josef, “The Birth, Early Years and Future of Interventional Radiology,” J Vasc Interv Radiol 2003; 14:841-853. |
Ross, F.R.C.S., D.N., “Aortic Valve Surgery,” Guy's Hospital, London, pp. 192-197, approximately 1968. |
Sabbah, Ph.D., Hani N., et al., “Mechanical Factors in the Degeneration of Porcine Bioprosthetic Valves: An Overview,” Journal of Cardiac Surgery, vol. 4, No. 4, pp. 302-309, Dec. 1989; ISSN 0886-0440. |
Selby, M.D., J. Bayne, “Experience with New Retrieval Forceps for Foreign Body Removal in the Vascular, Urinary, and Biliary Systems,” Radiology 1990; 176:535-538. |
Serruys, P.W., et al., “Stenting of Coronary Arteries. Are we the Sorcerer's Apprentice?,” European Heart Journal (1989) 10, 774-782, pp. 37-45, Jun. 13, 1989. |
Sigwart, Ulrich, “An Overview of Intravascular Stents: Old and New,” Chapter 48, Textbook of Interventional Cardiology, 2nd Edition, W.B. Saunders Company, Philadelphia, PA, © 1994, 1990, pp. 803-815. |
Uchida, Barry T., et al., “Modifications of Gianturco Expandable Wire Stents,” AJR:150, May 1988, Dec. 3, 1987, pp. 1185-1187. |
Urban, M.D., Philip, “Coronary Artery Stenting,” Editions Médecine et Hygiène, Genève, 1991, pp. 5-47. |
Watt, A.H., et al. “Intravenous Adenosine in the Treatment of Supraventricular Tachycardia; a Dose-Ranging Study and Interaction with Dipyridamole,” British Journal of Clinical Pharmacology (1986), 21, 227-230. |
Wheatley, M.D., David J., “Valve Prostheses,” Rob & Smith's Operative Surgery, Fourth Edition, pp. 415-424, Butterworths 1986. |
Number | Date | Country | |
---|---|---|---|
20210128300 A1 | May 2021 | US |
Number | Date | Country | |
---|---|---|---|
62040099 | Aug 2014 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16104015 | Aug 2018 | US |
Child | 17247676 | US | |
Parent | 14830347 | Aug 2015 | US |
Child | 16104015 | US |